A nurse has tragically died after receiving a weight loss injection in what is believed to be the first confirmed fatality ...

A 58 year old nurse has passed away after receiving a weight loss injection, marking the first reported death linked to the ...

Semaglutide remains on the agency’s drug shortage list, but all FDA-approved forms of the drug are no longer labeled ...

Susan McGowan, 58, died in September after taking two doses of the new generation of weight loss jabs known as GLP-1 agonists ...

The most popular GLP-1 agonist is semaglutide, known by the brand names Wegovy and Ozempic, andhere have been 23 suspected UK ...

Reports of “Ozempic parties” followed, and, as the drug’s popularity surged, supply became a drag in various countries.

In fact, one clinical trial indicated that only about 86% of the more than 800 participants achieved “clinically significant” weight loss after taking semaglutide, sold under the brands Ozempic and ...

Results were announced from a phase 3 clinical trial evaluating subcutaneous semaglutide in overweight patients with cardiovascular disease.

Recent studies have found that Ozempic could lead to more muscle mass loss than traditional weight loss methods.

A new study published in the New England Journal of Medicine showed that once-weekly injectable semaglutide led to ...

Drugmaker Lupin aims to be part of the first wave of generic drugmakers to make GLP-1 receptor agonists products, used to ...